Rare diseases
Investigational molecules
Locations
2a Chalmers Street, EH3 9ES, United Kingdom
Osteogenesis imperfecta is the central therapeutic focus, with research activity directed toward reducing fracture risk and improving skeletal outcomes in people affected by this inherited connective tissue disorder.
The sponsor’s research interest is concentrated on clinical approaches relevant to bone strength and the management of recurrent fractures in a rare paediatric and adult orthopaedic condition.
NHS Lothian runs clinical trials in conditions such as Osteogenesis imperfecta, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
DenmarkIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
